Global Health Supplies: Paradigm Shifts in Market Authorization, Procurement and Supply Chains Approaches

Joint UNICEF, UNFPA and WHO meeting with manufacturers and suppliers of in vitro diagnostic products, vaccines & immunization devices, finished pharmaceutical products, active pharmaceutical ingredients, contraceptive devices and vector control products 28 November - 01 December 2022, UN City, Copenhagen, Denmark



WHO Listed Authorities (WLA) and promoting reliance

Alireza Khadem Broojerdi

Team Lead, a.i. Regulatory System Strengthening [RSS] Regulation and Safety [REG] Regulation and Prequalification [RPQ] World Health Organization

Regulatory Updates

Context



• Resolution WHA 67.20 in 2014

 Recognized the importance of strong regulatory systems to a well-functioning healthcare system and the attainment of health-related SDGs and UHC

WHO supports Member States in reaching and sustaining effective regulatory oversight of medical products through the regulatory systems strengthening (RSS) programme Objectives of the RSS programme
Objectives of the RSS programme
Objectives of the RSS programme

good regulatory practices

Promote regulatory cooperation, convergence and transparency through networking, worksharing and reliance

Ultimate goal

Promote access to quality assured medical products

Objectives of WLA initiative

To provide a transparent and evidence-based pathway for RAs to be globally recognized

To promote access and the supply of safe, effective and quality medical products





Policy document:

The Policy describes the purpose, definitions and high-level operating principles related to the evaluation and public listing of authorities



Link: https://www.who.int/publications/i/item/9789240023444

WHO Listed Authorities framework







unicef 🚱


ONTERPA

World Health Organization





WLA initiative launched on 31st March 2022



A combined approach to achieve listing

WLA builds upon GBT

A WHO Listed Authority (WLA) is a regulatory authority or a regional regulatory system which has been documented to comply with all the relevant indicators and requirements specified by WHO for the requested scope of listing based on

unicef 🥴

• @ UNFPA

World Health

an established benchmarking (GBT) AND a performance evaluation (PE) process



WLA operating principles

01

02

03

04

Voluntary process initiated by a request from a member state



National Regulatory Authority (NRA) or Regional Regulatory System (RRS) are eligible



Regulatory Authorities must have attained overall Maturity Level 3 to be eligible for the PE process



unicef 🥴

Transitional WLAs are all eligible for the PE process




• • 🐨 UNFPA



World Health



Operating principles LISTING










Piloting the three pathways to WLA with three RAs



Standard

- GBT assessment conducted and ML4 attained

- PE indicators and tools under evaluation



Streamlined

- GBT and PE indicators evaluated
 - PE tools ongoing



Abridged

 Abridged tool under evaluation before piloting can be conducted

Comments from assessors and assessees, currently under collection, will inform the revision of

Interim OpG and Interim Manual for PE, by Q1 2023





Risk-based performance evaluation pathways

Evaluation pathway		Eligibility	Evaluation methodology
Transitional arrangements (tWLAs)	Abridged	SRAs for medicines and highly performing NRAs for vaccines	 RA self-assessment against pre-selected GBT and PE indicators that primarily target GRP and QMS WHO desktop review of self-assessment report
	Streamlined	ML3 and ML4 RAs (medicines and/or vaccines)	 RA self-assessment against pre-populated GBT, if needed, as well as PE indicators* WHO desktop review of self-assessment report WHO assessment against PEF**
		Regional reference RAs of the Americas (medicines and/or vaccines)	1. RA self-assessment against pre-populated GBT as well as PE indicators
		Functional RAs (vaccines)	 WHO desktop review of self-assessment; may involve an audit against selected GBT indicators to verify findings. WHO assessment against PEF
Routine arrangements (All other authorities)	Standard	Overall ML3 or ML4 RAs (medicines and/or vaccines) through GBT benchmarking	 RA self-assessment against PEF indicators (GBT ML4 + PE) WHO desktop review of self-assessment report WHO assessment against PEF

* The need for self-assessment against pre-populated GBT is dependent on outcome and validity of the earlier benchmarking. ** PEF consists of an audit of mandatory ML4 + PE indicators + evaluation of selected regulatory functions using PE tools





WLA process steps and estimated timelines

Colonder deve	Responsibilities		
Calendar days	WHO	RA	
1. Evaluation of Expression of Interest	30	\checkmark	N/A
2. Agreement on scope of listing and evaluation plan	60	\checkmark	\checkmark
3. Performance evaluation and report	60 – 180*	\checkmark	\checkmark
4. Technical WLA Advisory Group (TAG-WLA) opinion	60	\checkmark	N/A
5. Notice of Listing Decision (NOLD) and publication on WHO website	60	\checkmark	N/A

*Depending on the performance evaluation pathway, scope of listing and available evidence.



World Health Organization

Potential Benefits of WLA framework

Enable efficient use of regulatory resources

by providing a robust framework to promote **trust**, **confidence** and **reliance** Encourage continuous improvement of regulatory systems and regulatory convergence Help procurement decisions

on medical products by UN and other agencies, as well as countries (especially L<u>MIC)</u> Contributes to PQ programme

by expanding the pool of trusted regulatory authorities

Fosters health equity

by enabling an environment for innovation and local production, and accelerating access to medical products

Ongoing works and next steps







THANK YOU

Alireza Khadem Broojerdi

Team Lead, a.i. Regulatory System Strengthening [RSS] Regulation and Safety [REG] Regulation and Prequalification [RPQ] World Health Organization

Regulatory Updates

WHO